This article reviews ocular adverse events (AEs) reported in association with administration
of antibody–drug conjugates (ADCs) in human clinical trials. References reporting ocular …

Summation Cancer immunotherapy consists of approaches that modify the host immune
system, and/or the utilization of components of the immune system, as cancer treatment …

The majority of patients with acute myeloid leukaemia (AML) are elderly. Advancements in
supportive care and regimen intensification have resulted in improvements in clinical …

CD33 is expressed on the malignant blast cells in most cases of acute myeloid leukemia
(AML) but not on normal hematopoietic pluripotent stem cells. Antibody-based therapies for …

A diversity of coagulation disorders in cancer patients arise from tumor-specific growth
characteristics, neoangiogenesis with impaired endothelial lining, defective myelopoiesis …

The successful introduction of genetically engineered human and chimeric immunoglobulin
proteins has established monoclonal antibodies (mAbs) as a validated approach for treating …

BACKGROUND The development of newer strategies to improve outcomes for older
patients with secondary acute myeloid leukemia (s‐AML) is a critical unmet need …

Gemtuzumab Ozogamicin (GO) is an antibody-targeted chemotherapy agent consisting of
the humanized murine CD33 antibody (clone P67. 6) to which the calicheamicin-g1 …

The incidence of acute myeloid leukemia (AML) is increasing with age. As the results
associated with standard intensive chemotherapy remain particularly disappointing in older …

Gemtuzumab ozogamicin (GO) is a chemotherapeutic agent that consists of a humanized
anti-CD33 antibody (hP67. 6) linked to N-acetyl-calicheamicin 1, 2-dimethyl hydrazine …